Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Male breast cancer: a disease distinct from female breast cancer.

Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F.

Breast Cancer Res Treat. 2018 Sep 28. doi: 10.1007/s10549-018-4921-9. [Epub ahead of print] Review.

PMID:
30267249
2.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.

Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND.

Clin Cancer Res. 2018 Nov 1;24(21):5225-5232. doi: 10.1158/1078-0432.CCR-18-0564. Epub 2018 Jul 16.

PMID:
30012563
3.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 May 9. doi: 10.1007/s10549-018-4813-z. [Epub ahead of print]

PMID:
29744674
4.

Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK.

Horm Cancer. 2018 Apr;9(2):82-94. doi: 10.1007/s12672-017-0314-5. Epub 2018 Jan 16. Review.

PMID:
29340907
5.

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.

Sternberg CN, Baskin-Bey ES, Watson M, Worsfold A, Rider A, Tombal B.

BMC Urol. 2013 Nov 9;13:58. doi: 10.1186/1471-2490-13-58.

6.

Preliminary report of the Hepatic Encephalopathy Assessment Driving Simulator (HEADS) score.

Baskin-Bey ES, Stewart CA, Mitchell MM, Bida JP, Rosenthal TJ, Nyberg SL.

Ethn Dis. 2008 Summer;18(3):357-64.

PMID:
18785452
7.

Matching graft to recipient by predicted survival: can this be an acceptable strategy to improve utilization of deceased donor kidneys?

Baskin-Bey ES, Nyberg SL.

Transplant Rev (Orlando). 2008 Jul;22(3):167-70. doi: 10.1016/j.trre.2008.02.005. Epub 2008 Mar 28. Review.

PMID:
18631872
8.

Idiopathic benign biliary strictures in surgically resected patients with presumed cholangiocarcinoma.

Baskin-Bey ES, Devarbhavi HC, Nagorney DM, Farnell MB, Donohue JH, Sanderson SO, Stadheim LM, Gores GJ.

HPB (Oxford). 2005;7(4):283-8. doi: 10.1080/13651820500292954.

9.

Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse.

Baskin-Bey ES, Anan A, Isomoto H, Bronk SF, Gores GJ.

World J Gastroenterol. 2007 Nov 14;13(42):5635-41.

10.

A recipient risk score for deceased donor renal allocation.

Baskin-Bey ES, Kremers W, Nyberg SL.

Am J Kidney Dis. 2007 Feb;49(2):284-93.

PMID:
17261431
11.

Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury.

Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ.

Am J Transplant. 2007 Jan;7(1):218-25.

12.

Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology.

Baskin-Bey ES, Moreno Luna LE, Gores GJ.

J Hepatol. 2006 Oct;45(4):476-9. Epub 2006 Jul 25. Review. No abstract available.

PMID:
16901574
13.

Improving utilization of deceased donor kidneys by matching recipient and graft survival.

Baskin-Bey ES, Kremers W, Nyberg SL.

Transplantation. 2006 Jul 15;82(1):10-4.

PMID:
16861934
14.

Surgical triune.

Baskin-Bey ES.

Curr Surg. 2006 Jul-Aug;63(4):298-9. No abstract available.

PMID:
16843786
15.

Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins.

Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K, Craig RW, Moore DD, Gores GJ.

Hepatology. 2006 Jul;44(1):252-62.

PMID:
16799968
16.

Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.

Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G709-16. Epub 2006 Jun 22.

17.

Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.

van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ.

Liver Transpl. 2006 Mar;12(3):448-56.

18.

Proteasome inhibition induces hepatic stellate cell apoptosis.

Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ.

Hepatology. 2006 Feb;43(2):335-44.

PMID:
16440346
19.

Death by association: BH3 domain-only proteins and liver injury.

Baskin-Bey ES, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G987-90. Review.

20.

Caspase-8, death-receptor signaling, and hepatocarcinogenesis: the Fas and the furious.

Baskin-Bey ES, Gores GJ.

Gastroenterology. 2005 Nov;129(5):1790-2. No abstract available.

PMID:
16285976
21.

Treatment endpoints for advanced cholangiocarcinoma.

Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR.

Nat Clin Pract Gastroenterol Hepatol. 2004 Nov;1(1):4-5. No abstract available.

PMID:
16265019
22.

Improving the prediction of donor kidney quality: deceased donor score and resistive indices.

Nyberg SL, Baskin-Bey ES, Kremers W, Prieto M, Henry ML, Stegall MD.

Transplantation. 2005 Oct 15;80(7):925-9.

PMID:
16249740
23.

United Network for Organ Sharing's expanded criteria donors: is stratification useful?

Baskin-Bey ES, Kremers W, Stegall MD, Nyberg SL.

Clin Transplant. 2005 Jun;19(3):406-12.

PMID:
15877806
24.

Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury.

Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G396-402. Epub 2004 Oct 7.

Supplemental Content

Loading ...
Support Center